Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Caribou Biosciences Inc CRBU

Healthcare Biotechnology
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially... see more

Recent & Breaking News (NDAQ:CRBU)

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

GlobeNewswire April 15, 2024

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

GlobeNewswire April 4, 2024

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 11, 2024

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 5, 2024

Caribou Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire February 15, 2024

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

GlobeNewswire January 7, 2024

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

GlobeNewswire December 12, 2023

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 7, 2023

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

GlobeNewswire November 6, 2023

Caribou Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire November 1, 2023

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

GlobeNewswire October 18, 2023

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

GlobeNewswire September 27, 2023

Caribou Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire August 29, 2023

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 8, 2023

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

GlobeNewswire July 13, 2023

Caribou Biosciences Announces Proposed Public Offering of Common Stock

GlobeNewswire July 13, 2023

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

GlobeNewswire July 13, 2023

Caribou Biosciences Announces $25 Million Equity Investment from Pfizer

GlobeNewswire July 6, 2023

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire June 21, 2023

Caribou Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire May 31, 2023